Reported about 14 hours ago
In a recent analysis, Jim Cramer's predictions on Bristol-Myers Squibb Company (BMY) were scrutinized, noting that while he initially expressed concerns about its growth potential, the stock has since risen by over 13%. Despite earlier doubts regarding its pipeline, Cramer has become more optimistic about BMY's prospects, especially with the anticipated success of a schizophrenia drug. The discussion highlights Cramer's broader views on stock market participation among everyday Americans.
Source: YAHOO